At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AEMD Aethlon Medical
Post-Mkt 12-22 18:33:07 EST
2.88
+0.02
+0.70%
盘后2.93
+0.05+1.74%
17:10 EST
High2.98Low2.88Vol18.43K
Open2.90D1 Closing2.86Amplitude3.32%
Mkt Cap2.19MTradable Cap2.07MTotal Shares761.20K
T/O53.74KT/O Rate2.56%Tradable Shares720.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Aethlon Medical Announces Pricing Of A Private Placement And Warrant Inducement
Reuters  ·  12-05
BRIEF-Aethlon Medical Announces Pricing Of A Private Placement And Warrant Inducement
Press Release: Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Dow Jones  ·  12-05
Press Release: Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study
Reuters  ·  12-02
Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study
Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)
TIPRANKS  ·  11-14
Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)
Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress
Reuters  ·  11-13
Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress
Aethlon Medical Q2 EPS $(3.74) Misses $(3.66) Estimate
Benzinga  ·  11-13
Aethlon Medical Q2 EPS $(3.74) Misses $(3.66) Estimate
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
THOMSON REUTERS  ·  11-13
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Aethlon Medical Inc - Qtrly Loss per Share $3.74
THOMSON REUTERS  ·  11-13
Aethlon Medical Inc - Qtrly Loss per Share $3.74
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-12
Calendar of U.S. Earnings Expected in the Week Ahead
Aethlon Medical Inc expected to post a loss of $3.66 a share - Earnings Preview
Reuters  ·  11-08
Aethlon Medical Inc expected to post a loss of $3.66 a share - Earnings Preview
Aethlon Medical Inc. to Report Fiscal Second Quarter Results
Reuters  ·  11-07
Aethlon Medical Inc. to Report Fiscal Second Quarter Results
Aethlon Medical Regains Nasdaq Compliance After Stock Surge
TIPRANKS  ·  11-06
Aethlon Medical Regains Nasdaq Compliance After Stock Surge
Aethlon Medical Inc - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing
THOMSON REUTERS  ·  11-06
Aethlon Medical Inc - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing
Aethlon Medical Faces Nasdaq Non-Compliance Notice
TIPRANKS  ·  10-23
Aethlon Medical Faces Nasdaq Non-Compliance Notice
Aethlon Medical Faces Nasdaq Delisting After Failing Minimum Bid Price Requirement
Reuters  ·  10-23
Aethlon Medical Faces Nasdaq Delisting After Failing Minimum Bid Price Requirement
Aethlon Medical trading halted, news pending
TIPRANKS  ·  10-18
Aethlon Medical trading halted, news pending
Aethlon Medical Inc - Authorizes 1-for-10 Reverse Stock Split - SEC Filing
THOMSON REUTERS  ·  10-16
Aethlon Medical Inc - Authorizes 1-for-10 Reverse Stock Split - SEC Filing
Aethlon Medical Announces 1-for-10 Reverse Stock Split Effective October 16, 2025
Reuters  ·  10-16
Aethlon Medical Announces 1-for-10 Reverse Stock Split Effective October 16, 2025
BRIEF-Aethlon Medical's Hemopurifier® Shows Changes In Extracellular Vesicles, Extracellular Micrornas, And T Cell Numbers In Australian Oncology Clinical Trial
Reuters  ·  10-07
BRIEF-Aethlon Medical's Hemopurifier® Shows Changes In Extracellular Vesicles, Extracellular Micrornas, And T Cell Numbers In Australian Oncology Clinical Trial
Aethlon Medical Announces Promising Early Data from Australian Clinical Trial of Hemopurifier® in Cancer Patients Resistant to Anti-PD-1 Therapy
Reuters  ·  10-07
Aethlon Medical Announces Promising Early Data from Australian Clinical Trial of Hemopurifier® in Cancer Patients Resistant to Anti-PD-1 Therapy

Introduction

Company Name.
Aethlon Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Issue price:
--